Xoma reported $263.15M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
AbbVie USD 133.96B 62M Dec/2025
Agenus USD 226.8M 7.09M Dec/2025
Agios Pharmaceuticals USD 1.3B 88.48M Dec/2025
Ardelyx USD 501.6M 15.43M Dec/2025
aTyr Pharma USD 515.34M 408.68M Dec/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Celldex Therapeutics USD 582.98M 65.46M Dec/2025
Curis USD 19.97M 9.27M Dec/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Emergent BioSolutions USD 1.82B 69.9M Dec/2023
Incyte USD 6.96B 627.62M Dec/2025
MacroGenics USD 256.85M 13.92M Dec/2025
Novartis USD 110.95B 3.66B Dec/2025
Novartis USD 110.95B 3.66B Dec/2025
Pfizer USD 208.73B 2.64B Sep/2025
Prothena USD 326.8M 25.82M Dec/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Xoma USD 263.15M 39.7M Sep/2025